We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+29.4%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.45B
AUM Growth
+$253M
Cap. Flow
-$255M
Cap. Flow %
-7.4%
Top 10 Hldgs %
43.88%
Holding
127
New
16
Increased
25
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$62.7M
2
BLU
BELLUS Health Inc.
BLU
+$50.1M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$48.2M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$42.4M
5
EW icon
Edwards Lifesciences
EW
+$31.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$38.2M
2
LLY icon
Eli Lilly
LLY
+$32.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.2M
5
CHRS icon
Coherus Oncology
CHRS
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 98.21%
2 Miscellaneous 1.6%
3 Financials 0.19%
4 Consumer Staples 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
51
Coherus Oncology
CHRS
$205M
$16M 0.47%
1,667,123
-1,978,348
-54% -$20M
VRCA icon
52
Verrica Pharmaceuticals
VRCA
$78.7M
$14.7M 0.43%
503,898
– –
AKRO
53
DELISTED
Akero Therapeutics
AKRO
$14.6M 0.42%
+430,000
New +$6.58M
CNCE
54
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$14.4M 0.42%
2,150,641
– –
LONA
55
LeonaBio Inc
LONA
$68.2M
$14.2M 0.41%
479,728
– –
PRTA icon
56
Prothena Corp
PRTA
$428M
$13.9M 0.4%
+230,000
New +$7.27M
DICE
57
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$13.9M 0.4%
687,424
-364,480
-35% -$6.64M
HLVX
58
DELISTED
HilleVax
HLVX
$13.1M 0.38%
764,907
– –
RAIN
59
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$12.1M 0.35%
2,483,619
– –
ATXS
60
DELISTED
Astria Therapeutics
ATXS
$11.6M 0.34%
1,281,197
– –
AXGN icon
61
Axogen
AXGN
$2.42B
$11.3M 0.33%
+949,626
New +$9.5M
PRCT icon
62
Procept Biorobotics
PRCT
$1.11B
$10.9M 0.32%
263,720
-485,980
-65% -$19.4M
NBIX icon
63
Neurocrine Biosciences
NBIX
$15.2B
$10.6M 0.31%
100,050
-297,838
-75% -$30.2M
MORF
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$10.3M 0.3%
363,197
– –
CCXI
65
DELISTED
ChemoCentryx, Inc.
CCXI
$9.95M 0.29%
192,680
-249,000
-56% -$10.3M
LABP
66
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$9.66M 0.28%
1,486,992
– –
LRMR icon
67
Larimar Therapeutics
LRMR
$406M
$9.15M 0.27%
+2,860,000
New +$7.16M
OMIC
68
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$8.84M 0.26%
117,876
– –
RCKT icon
69
Rocket Pharmaceuticals
RCKT
$374M
$7.98M 0.23%
500,000
-666,883
-57% -$10.4M
KRON
70
DELISTED
Kronos Bio
KRON
$7.22M 0.21%
2,156,151
-264,991
-11% -$1.2M
ISO
71
DELISTED
IsoPlexis Corporation Common Stock
ISO
$7.04M 0.2%
4,095,498
– –
NVRO
72
DELISTED
NEVRO CORP.
NVRO
$6.99M 0.2%
+150,000
New +$6.96M
CCCC icon
73
C4 Therapeutics
CCCC
$422M
$6.72M 0.2%
766,231
– –
CYPH
74
Cypherpunk Technologies Inc
CYPH
$239M
$6.58M 0.19%
747,215
-47,930
-6% -$582K
SLDB icon
75
Solid Biosciences
SLDB
$897M
$6.26M 0.18%
894,170
– –
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Perceptive Advisors held 127 positions worth $3.45B, up 7.9% from $3.19B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $255M in Q3 2022, closing 11 positions and reducing 24 holdings. Its most notable exit was Eli Lilly, an estimated $32.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Edwards Lifesciences worth $27.3M.

  • Perceptive Advisors's largest Q3 2022 buy was Edwards Lifesciences: 330,000 shares worth $27.3M.
  • Perceptive Advisors added most to Relmada Therapeutics in Q3 2022, an estimated $62.7M increase.
  • Perceptive Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $38.2M.
  • Perceptive Advisors fully exited Eli Lilly in Q3 2022, selling an estimated $32.4M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q3 2022.
  • Perceptive Advisors opened 16 new positions and closed 11 in Q3 2022.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.